plerixafor (mozobil) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Plerixafor is a bicyclam molecule, which has been identified as a specific antagonist of CXCR4. It had originally been developed as an inhibitor of T-tropic human immunodeficiency virus, but later demonstrated to be an effective mobilizer of hematopoietic stem cells. Plerixafor was approved by FDA for autologous transplantation (in combination with granulocyte-colony stimulating factor) in patients with non-Hodgkin's lymphoma and multiple myeloma under the name Mozobil.   NCATS

Chemistry

  • SMILES: C(N1CCCNCCNCCCNCC1)C2=CC=C(CN3CCCNCCNCCCNCC3)C=C2
  • InChIKey: YIQPUIGJQJDJOS-UHFFFAOYSA-N
  • Mol. Mass: 502.782
  • ALogP: 0.42
  • ChEMBL Molecule:
    plerixafor  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$5149.1162

United States

$6971.7960 - $9493.9920
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1,1'-(1,4-phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate | 1,1'-(1,4-phenylenebis(methylene))bis(1,4,8,11-tetraazacyclotetradecane)octahydrochloride dihydrate | amd3100 | amd 3100 | amd-3100 | amd 3329 | amd-3329 | bicyclam | gz316455 | jm3100 | jm 3100 | jm-3100 | mezobil | mozobil | perixafor | plerixafor | plerixafor hydrochloride | rpa bicyclam

Organizations (112)

Research & Development (105)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (85)

Approved Indications (2)


 

Lymphoma, Non-Hodgkin (approved 2008)

Multiple Myeloma (approved 2008)

Experimental Indications - Clinical Trial Phases 1-4 (85)


 

Agammaglobulinemia (Phase 3)

Allografts (Phase 2)

Anemia, Sickle Cell (Phase 2)

Astrocytoma (Phase 1)

beta-Thalassemia (Phase 1/Phase 2)

Biomarkers (Phase 1)

Blood Circulation (Phase 2)

Bone Marrow Cells (Phase 2)

Bone Marrow Failure Disorders (Phase 1/Phase 2)

Bone Marrow Transplantation (Phase 2)

Brain Neoplasms (Phase 1/Phase 2)

Chronic Limb-Threatening Ischemia (Phase 2)

Colorectal Neoplasms (Phase 1)

COVID-19 (Phase 2)

Cystic Fibrosis (Phase 1)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 1/Phase 2)

Endometrial Neoplasms (Early Phase 1)

End Stage Liver Disease (Phase 1)

Fanconi Anemia (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Gliosarcoma (Phase 2)

Granuloma (Phase 2)

Granulomatous Disease, Chronic (Phase 2)

Gynatresia (Early Phase 1)

Head and Neck Neoplasms (Phase 2)

Healthy Volunteers (Phase 2)

Hematologic Neoplasms (Phase 2)

Hematopoietic Stem Cell Mobilization (Phase 2)

Hematopoietic Stem Cells (Phase 2)

Hematopoietic Stem Cell Transplantation (Phase 4)

HIV (Phase 1)

Hodgkin Disease (Phase 3)

Infections (Phase 3)

Kidney Failure, Chronic (Phase 1)

Leukemia (Phase 1/Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Leukopenia (Phase 1)

Living Donors (Phase 2)

Lymphoma (Phase 4)

Lymphoma, Follicular (Phase 1/Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 1/Phase 2)

Lymphoma, Non-Hodgkin (Phase 4)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Lymphopenia (Phase 2)

Medulloblastoma (Phase 1/Phase 2)

Multiple Myeloma (Phase 4)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 3)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Neuroblastoma (Phase 1/Phase 2)

Neuroectodermal Tumors (Phase 1/Phase 2)

Neutropenia (Phase 3)

Oligodendroglia (Phase 2)

Oligodendroglioma (Phase 1)

Organ Transplantation (Phase 1/Phase 2)

Osteosarcoma (Phase 1)

Ovarian Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostheses and Implants (Early Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Pulmonary Fibrosis (Phase 1)

Sarcoma (Phase 1)

Sarcoma, Ewing (Phase 1/Phase 2)

Sarcoma, Myeloid (Phase 2)

Scleroderma, Systemic (Phase 2)

Severe Combined Immunodeficiency (Phase 2)

Stem Cells (Phase 2)

Stem Cell Transplantation (Phase 1/Phase 2)

T-Lymphocytopenia, Idiopathic CD4-Positive (Phase 2)

Transplantation (Phase 3)

Transplantation, Autologous (Phase 2)

Warts (Phase 3)

Wiskott-Aldrich Syndrome (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 141
  • # of Trial Organizations: 105

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue